Screener
ImmunityBio, Inc. IBRX Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of derivative liabilities | 1,108 | 5,578 |
| Interest expense | (34) | (18) |
| Other expense, net | (5,917) | (41) |
| Total other expense, net | (562,997) | (65,471) |
| Loss before income taxes and noncontrolling interest | (632,788) | (129,900) |
| Income tax (expense) benefit | (9) | 234 |
| Net loss | (632,797) | (129,666) |
| Net loss attributable to noncontrolling interests, net of tax | (15) | (20) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s other income (expense)?
- ImmunityBio, Inc. (IBRX) reported other income (expense) of -$563M in Q1 2026.
- How has ImmunityBio, Inc.'s other income (expense) changed year-over-year?
- ImmunityBio, Inc.'s other income (expense) decreased by 759.9% year-over-year, from -$65.47M to -$563M.
- What is the long-term trend for ImmunityBio, Inc.'s other income (expense)?
- Over 3 years (2021 to 2025), ImmunityBio, Inc.'s other income (expense) has grown at a 71.2% compound annual growth rate (CAGR), from -$19.56M to -$98.17M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about ImmunityBio, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude